Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.

Sanofi

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SANOFI'S TEIZEILD RECOMMENDED FOR EU APPROVAL BY THE CHMP FOR PATIENTS WITH STAGE 2 TYPE 1 DIABETES RECOMMENDATION BASED ON THE TN-10 STUDY, DEMONSTRATING TEIZEILD'S ABILITY TO DELAY THE ONSET OF STAGE 3 TYPE 1 DIABETES (T1D), COMPARED TO PLACEBO, IN ADULTS AND CHILDREN WITH STAGE 2 T1D IF APPROVED, TEIZEILD WOULD BECOME THE FIRST DISEASE-MODIFYING T1D THERAPY IN THE EU PARIS, NOVEMBER 14, 2025. THE EUROPEAN MEDICINES AGENCY (EMA)'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ADOPTED A POSITIVE OPINION RECOMMENDING THE APPROVAL OF TEIZEILD (TEPLIZUMAB) TO DELAY THE ONSET OF STAGE 3 T1D IN ADULT AND PEDIATRIC PATIENTS EIGHT YEARS OF AGE AND OLDER WITH STAGE 2 T1D.

PRESS RELEASE: SANOFI'S TEIZEILD RECOMMENDED FOR EU APPROVAL BY THE CHMP FOR PATIENTS WITH STAGE 2 TYPE 1 DIABETES

ACAAI: SANOFI AND REGENERON'S DUPIXENT PIVOTAL STUDY MET ALL PRIMARY AND SECONDARY ENDPOINTS, REDUCING SIGNS AND SYMPTOMS OF ALLERGIC FUNGAL RHINOSINUSITIS; SBLA ACCEPTED FOR FDA PRIORITY REVIEW

PRESS RELEASE: ACAAI: SANOFI AND REGENERON'S DUPIXENT PIVOTAL STUDY MET ALL PRIMARY AND SECONDARY ENDPOINTS, REDUCING SIGNS AND SYMPTOMS OF ALLERGIC FUNGAL RHINOSINUSITIS; SBLA ACCEPTED FOR FDA PRIORITY REVIEW

MEDIDATA EXTENDS COLLABORATION WITH SANOFI FOR THE DEVELOPMENT OF NEW THERAPIES WITH AN IMPROVED PATIENT JOURNEY

UPDATE: DASSAULT SYSTMES: MEDIDATA EXTENDS COLLABORATION WITH SANOFI FOR THE DEVELOPMENT OF NEW THERAPIES WITH AN IMPROVED PATIENT JOURNEY

EXPANDED 10-PLUS-YEAR COLLABORATION WILL LEVERAGE MEDIDATA EXPERIENCES WITH THE GOAL OF STREAMLINING CLINICAL PROCESSES AND DATA, ENHANCING PATIENT CARE EXPANDED 10-PLUS-YEAR COLLABORATION WILL LEVERAGE MEDIDATA EXPERIENCES WITH THE GOAL OF STREAMLINING CLINICAL PROCESSES AND DATA, ENHANCING PATIENT CARE

UPDATE - MEDIDATA EXTENDS COLLABORATION WITH SANOFI FOR THE DEVELOPMENT OF NEW THERAPIES WITH AN IMPROVED PATIENT JOURNEY

Q3: CONTINUED SALES AND EARNINGS PROGRESS PARIS, OCTOBER 24, 2025 Q3 SALES GROWTH OF 7.0% AT CER1 AND BUSINESS EARNINGS PER SHARE (EPS)2 OF 2.91 PHARMA LAUNCHES INCREASED SALES BY 57.1%, REACHING 1.0 BILLION, DRIVEN BY ALTUVIIIO AND AYVAKIT DUPIXENT SALES INCREASED BY 26.2% TO 4.2 BILLION, FIRST TIME ABOVE 4 BILLION IN A QUARTER VACCINES SALES DECREASED BY 7.8% TO 3.4 BILLION, FROM LOWER INFLUENZA SALES RESEARCH AND DEVELOPMENT EXPENSES WERE 1.8 BILLION, AN INCREASE OF 4.9% SELLING, GENERAL AND ADMINISTRATIVE EXPENSES WERE 2.3 BILLION, UP 7.1% TO SUPPORT LAUNCHES BUSINESS EPS WAS 2.91, UP 13.2% AT CER AND 7.0% AT ACTUAL EXCHANGE RATES, DELIVERING PROFITABLE GROWTH; IFRS EPS WAS 2.30 PIPELINE PROGRESS TWO REGULATORY APPROVALS: WAYRILZ (US) IN ITP, A RARE DISEASE, AND TZIELD (CHINA) FOR DELAYING ONSET OF STAGE 3, TYPE 1 DIABETES TWO POSITIVE PHASE 3 READOUTS: AMLITELIMAB'S FIRST PHASE 3 STUDY IN ATOPIC DERMATITIS AND FLUZONE HD IN INFLUENZA 50+ YEARS EIGHT REGULATORY SUBMISSION ACCEPTANCES, THREE PHASE 3 STUDY STARTS, AND THREE REGULATORY DESIGNATIONS (FAST TRACK, ORPHAN) CAPITAL ALLOCATION COMPLETION OF THE VIGIL NEUROSCIENCE ACQUISITION, ADDING TO THE EARLY-STAGE PIPELINE ADDITIONAL COMMITMENT OF $625 MILLION TO SANOFI VENTURES, INVESTING IN INNOVATIVE BIOTECH AND DIGITAL HEALTH COMPANIES SANOFI INTENDS TO COMPLETE ITS 5 BILLION SHARE BUYBACK PROGRAM IN 2025. 86.1% HAS BEEN EXECUTED TO DATE SUSTAINABILITY GLOBAL HEALTH UNIT: ONE MILLION PATIENTS HAVE NOW RECEIVED TREATMENTS FOR NON-COMMUNICABLE DISEASES SINCE 2021 INSULINS VALYOU SAVINGS PROGRAM: IMPROVING ACCESS TO RELIABLE AND AFFORDABLE SUPPLY OF CRITICAL MEDICINES IN THE US GUIDANCE UNCHANGED IN 2025, SALES ARE ANTICIPATED TO GROW BY A HIGH SINGLE-DIGIT PERCENTAGE AT CER.

PRESS RELEASE: Q3: CONTINUED SALES AND EARNINGS PROGRESS

EXPANDED 10-PLUS-YEAR COLLABORATION WILL LEVERAGE MEDIDATA EXPERIENCES, ENABLING SANOFI TO STREAMLINE OPERATIONS, REFINE DATA QUALITY, AND ENHANCE PATIENT CARE EXPANDED 10-PLUS-YEAR COLLABORATION WILL LEVERAGE MEDIDATA EXPERIENCES, ENABLING SANOFI TO STREAMLINE OPERATIONS, REFINE DATA QUALITY, AND ENHANCE PATIENT CARE

SANOFI DEEPENS PARTNERSHIP WITH MEDIDATA TO EXPEDITE THE DEVELOPMENT OF NEW THERAPIES WITH AN IMPROVED PATIENT JOURNEY

DASSAULT SYSTMES: SANOFI DEEPENS PARTNERSHIP WITH MEDIDATA TO EXPEDITE THE DEVELOPMENT OF NEW THERAPIES WITH AN IMPROVED PATIENT JOURNEY

SANOFI'S EFDORALPRIN ALFA MET ALL PRIMARY AND KEY SECONDARY ENDPOINTS IN ALPHA-1 ANTITRYPSIN DEFICIENCY EMPHYSEMA PHASE 2 STUDY

PRESS RELEASE: SANOFI'S EFDORALPRIN ALFA MET ALL PRIMARY AND KEY SECONDARY ENDPOINTS IN ALPHA-1 ANTITRYPSIN DEFICIENCY EMPHYSEMA PHASE 2 STUDY

SANOFI'S TZIELD ACCEPTED FOR EXPEDITED REVIEW IN THE US FOR STAGE 3 TYPE 1 DIABETES THROUGH FDA COMMISSIONER'S NATIONAL PRIORITY VOUCHER PILOT PROGRAM

PRESS RELEASE: SANOFI'S TZIELD ACCEPTED FOR EXPEDITED REVIEW IN THE US FOR STAGE 3 TYPE 1 DIABETES THROUGH FDA COMMISSIONER'S NATIONAL PRIORITY VOUCHER PILOT PROGRAM

ESMO: ALPHAMEDIX TM PHASE 2 DATA SUPPORT FIRST-IN-CLASS POTENTIAL OF NEW TARGETED ALPHA THERAPY IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS NEW ALPHAMEDIX DATA SHOWED SUSTAINED AND CLINICALLY MEANINGFUL RESPONSES ACROSS BOTH RLT-NAVE AND RLT-EXPOSED PATIENTS WITH UNRESECTABLE OR METASTATIC GEP-NETS FIRST PHASE 2 STUDY TO EVALUATE TAT WITH LEAD-212 SUPPORTING ITS POTENTIAL TO ADDRESS HIGH UNMET MEDICAL NEEDS IN DIFFICULT-TO-TREAT, RARE CANCERS PHASE 2 STUDY MET ALL PRIMARY EFFICACY ENDPOINTS AND WAS PRESENTED ACROSS TWO ORAL PRESENTATIONS AT THE 2025 ESMO CONGRESS IN BERLIN, GERMANY PARIS, OCTOBER 20, 2025.NEW DATA FROM THE ALPHAMEDIX-02 PHASE 2 STUDY (CLINICAL STUDY IDENTIFIER: NCT05153772) EVALUATING ALPHAMEDIX (212PB-DOTAMTATE), AN INVESTIGATIONAL SOMATOSTATIN RECEPTOR (SSTR) TARGETED ALPHA THERAPY (TAT) USING THE LEAD-212 ISOTOPE, UNDERSCORE THE FIRST-IN-CLASS POTENTIAL OF THIS INVESTIGATIONAL MEDICINE FOR THE TREATMENT OF PATIENTS WITH ADVANCED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS).

PRESS RELEASE: ESMO: ALPHAMEDIXTM PHASE 2 DATA SUPPORT FIRST-IN-CLASS POTENTIAL OF NEW TARGETED ALPHA THERAPY IN GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS

SANOFI'S HIGH-DOSE INFLUENZA VACCINE DEMONSTRATES SUPERIOR PROTECTION FOR OLDER ADULTS AGAINST HOSPITALIZATION VS STANDARD-DOSE

PRESS RELEASE: SANOFI'S HIGH-DOSE INFLUENZA VACCINE DEMONSTRATES SUPERIOR PROTECTION FOR OLDER ADULTS AGAINST HOSPITALIZATION VS STANDARD-DOSE

SANOFI'S WAYRILZ RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT IMMUNE THROMBOCYTOPENIA RECOMMENDATION BASED ON LUNA 3 PHASE 3 STUDY DEMONSTRATING RAPID AND DURABLE PLATELET RESPONSE AND SIGNIFICANT IMPROVEMENTS IN BLEEDING, QUALITY OF LIFE MEASURES, AND OTHER ITP SYMPTOMS IF APPROVED, WAYRILZ WILL BE THE FIRST BTK INHIBITOR FOR ITP IN THE EU, TARGETING THE ROOT CAUSE OF THE DISEASE THROUGH MULTI-IMMUNE MODULATION PARIS, OCTOBER 17, 2025. THE EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ADOPTED A POSITIVE OPINION RECOMMENDING THE APPROVAL OF WAYRILZ (RILZABRUTINIB) AS A NEW TREATMENT FOR IMMUNE THROMBOCYTOPENIA (ITP) IN ADULT PATIENTS WHO ARE REFRACTORY TO OTHER TREATMENTS.

PRESS RELEASE: SANOFI'S WAYRILZ RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT IMMUNE THROMBOCYTOPENIA

SANOFI PROVIDES UPDATE ON REGULATORY REVIEW IN THE EU FOR REZUROCK TO TREAT CHRONIC GRAFT-VS-HOST DISEASE PARIS, OCTOBER 17, 2025. THE EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ISSUED A NEGATIVE OPINION ON THE MARKETING AUTHORISATION APPLICATION FOR REZUROCK (BELUMOSUDIL) FOR THE THIRD-LINE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD).

PRESS RELEASE: SANOFI PROVIDES UPDATE ON REGULATORY REVIEW IN THE EU FOR REZUROCK TO TREAT CHRONIC GRAFT-VS-HOST DISEASE

CHICAGO , OCT. 16, 2025 /PRNEWSWIRE/ -- EVOQ THERAPEUTICS, INC. (EVOQ), A BIOTECHNOLOGY COMPANYFOCUSED ON DELIVERING TRANSFORMATIVE CURES FOR THOSE LIVING WITH AUTOIMMUNE DISEASES, TODAYANNOUNCED A COLLABORATION AND LICENSE AGREEMENT WITH SANOFI, AN R&D DRIVEN, AI-POWEREDBIOPHARMA COMPANY, COMMITTED TO IMPROVING PEOPLE'S LIVES AND DELIVERING COMPELLING GROWTH. SANOFI IS LISTED ON EURONEXT: SAN AND NASDAQ: SNY EVOQ'S PROPRIETARY BREAKTHROUGH NANODISC TECHNOLOGY RESTORES THE BODY'S NATURAL IMMUNETOLERANCE PATHWAYS AND OPENS THE DOOR FOR A WIDE RANGE OF DISEASE-SPECIFIC, CURATIVE THERAPIESFOR MULTIPLE AUTOIMMUNE DISEASES LIKE CELIAC DISEASE, TYPE 1 DIABETES, MOG (MYELINOLIGODENDROCYTE GLYCOPROTEIN) ANTIBODY DISEASE, RHEUMATOID ARTHRITIS AND LUPUS.

EVOQ THERAPEUTICS ANNOUNCES COLLABORATION AND LICENSE AGREEMENT WITH SANOFI

GARCHING / MUNICH, GERMANY, OCTOBER 13, 2025  ITM ISOTOPE TECHNOLOGIES MUNICH SE (ITM), A LEADING RADIOPHARMACEUTICAL BIOTECH COMPANY, TODAY ANNOUNCED THE APPOINTMENT OF ANNETTE BREUNIG AS CHIEF PEOPLE OFFICER (CPO). MS. BREUNIG BRINGS OVER 25 YEARS OF HR LEADERSHIP EXPERIENCE AT INTERNATIONAL PHARMACEUTICAL, MANUFACTURING AND TECHNOLOGY COMPANIES, INCLUDING AT SIEMENS AG (FRA: SIE) AND SANOFI (NASDAQ: SNY). AT ITM, MS. BREUNIG WILL LEAD THE HR TEAM IN SHAPING STRATEGIES THAT UNIFY THE ORGANIZATION TO ACHIEVE BOTH TEAM AND BUSINESS GROWTH OBJECTIVES WHILE EMPOWERING EMPLOYEES, STRENGTHENING COMPANY CULTURE AND ATTRACTING TOP TALENT. ANNETTE'S DEDICATION TO SUPPORTING TOP-PERFORMING TEAMS AT GLOBAL, HIGH-GROWTH COMPANIES HAS CREATED DYNAMIC WORK ENVIRONMENTS. AS ITM CONTINUES SCALING ITS ORGANIZATION TO MEET THE NEEDS OF PEOPLE LIVING WITH CANCER, HER LEADERSHIP WILL BE A GREAT ADDITION, SAID DR. ANDREW CAVEY, CEO OF ITM. OUR PEOPLE ARE THE CORE THAT DRIVE OUR SUCCESS. THIS APPOINTMENT FURTHER STRENGTHENS OUR HR TEAM'S ABILITY TO ELEVATE EMPLOYEES AND ENSURES THAT ITM REMAINS A GREAT PLACE TO WORK AS WE ADVANCE OUR MISSION TO DEVELOP INNOVATIVE RADIOPHARMACEUTICALS . AS EXECUTIVE VICE PRESIDENT OF PEOPLE & CULTURE AT INFIOS GROUP (FORMERLY KRBER SUPPLY CHAIN SOFTWARE), ANNETTE LED THE INTEGRATION OF THE COMPANY'S WORKFORCE ACROSS 10 COUNTRIES IN ASIA, EUROPE, AND THE UNITED STATES INTO A COHESIVE AND UNIFIED GLOBAL CULTURE. AS VICE PRESIDENT OF HR AT KRBER SUPPLY CHAIN GROUP AND AT KRBER PHARMA SHE ESTABLISHED GLOBAL HR TEAMS, DEVELOPED AND IMPLEMENTED THE COMPANIES' GLOBAL PEOPLE STRATEGIES, AND LAUNCHED MAJOR GLOBAL CULTURE INITIATIVES. ANNETTE ALSO HELD GLOBAL SENIOR LEADERSHIP AND MANAGEMENT ROLES FOR MORE THAN TEN YEARS AT SIEMENS AG, WHERE SHE OVERSAW STRATEGIC AND OPERATIONAL HR FUNCTIONS, INCLUDING THE DEVELOPMENT OF SYSTEMS FOR HIRING AND DEVELOPING BEST-IN-CLASS TALENT, AND THE DESIGNED COMPENSATION STRATEGIES AND POLICIES. SHE ALSO WORKED IN SENIOR MANAGEM

ITM APPOINTS ANNETTE BREUNIG AS CHIEF PEOPLE OFFICER

TORONTO--(BUSINESS WIRE)--BENCHSCI ANNOUNCES THREE-YEAR LICENSE AGREEMENT WITH SANOFI TO ACCESS AND USE BENCHSCI'S ASCEND PLATFORM.

BENCHSCI ANNOUNCES THREE-YEAR LICENSE AGREEMENT WITH SANOFI TO ACCESS AND USE BENCHSCI'S ASCEND PLATFORM

ALPHAMEDIX TM ( 212 PB-DOTAMTATE) ACHIEVED ALL PRIMARY EFFICACY ENDPOINTS IN PHASE 2 STUDY, DEMONSTRATING CLINICALLY MEANINGFUL BENEFITS IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS

PRESS RELEASE: ALPHAMEDIXTM (212PB-DOTAMTATE) ACHIEVED ALL PRIMARY EFFICACY ENDPOINTS IN PHASE 2 STUDY, DEMONSTRATING CLINICALLY MEANINGFUL BENEFITS IN PATIENTS WITH GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS

WALTHAM, MASS.--(BUSINESS WIRE)--REVVITY, INC. (NYSE: RVTY) TODAY ANNOUNCED A PROGRAM FOR EXPANSION OF ITS TYPE 1 DIABETES (T1D) OFFERING TO INCLUDE A POPULATION-SCALE ASSAY FOR EARLY DETECTION WITH SUPPORT FROM SANOFI (EURONEXT: SAN AND NASDAQ: SNY). REVVITY WILL DEVELOP A T1D 4-PLEX IN VITRO DIAGNOSTIC (IVD) ASSAY BASED ON ITS EXISTING RESEARCH-USE (RUO) 3-PLEX ASSAY. T1D IS A LIFELONG, PROGRESSIVE AUTOIMMUNE CONDITION THAT OCCURS WHEN THE IMMUNE SYSTEM MISTAKENLY ATTACKS THE INSULIN-PRODUCIN.

REVVITY ANNOUNCES PROGRAM TO REVOLUTIONIZE THE EARLY DETECTION OF TYPE 1 DIABETES

TEL AVIV, ISREAL & CAMBRIDGE, MASS.--(BUSINESS WIRE)--QUANTHEALTH, A PIONEER IN AI-DRIVEN CLINICAL TRIAL SIMULATION, ANNOUNCED A STRATEGIC INVESTMENT FROM SANOFI VENTURES, THE VENTURE CAPITAL ARM OF GLOBAL HEALTHCARE LEADER SANOFI. THE INVESTMENT WILL ACCELERATE QUANTHEALTH'S EFFORTS TO BRING SCALABLE, PATIENT-LEVEL SIMULATIONS AND DIGITAL TWIN TECHNOLOGIES TO THE FOREFRONT OF DRUG DEVELOPMENT, BRINGING ITS TOTAL FUNDS RAISED TO $30 MILLION. QUANTHEALTH'S PLATFORM ENABLES PHARMACEUTICAL COMPANI.

QUANTHEALTH SECURES STRATEGIC INVESTMENT FROM SANOFI VENTURES TO ACCELERATE AI-DRIVEN CLINICAL TRIALS

MORRISTOWN, N.J. , SEPT. 26, 2025 /PRNEWSWIRE/ -- SANOFI US TODAY ANNOUNCES A BROAD EXPANSION OF ITS INSULINS VALYOU SAVINGS PROGRAM BY OFFERING A 30-DAY SUPPLY OF ANY SANOFI INSULIN FOR $35 TO ALL PATIENTS IN THE US WITH A VALID PRESCRIPTION.

SANOFI EXPANDS PATIENT AFFORDABILITY PROGRAM BY OFFERING ACCESS TO ALL ITS INSULINS FOR $35 PER MONTH IN THE US

SANOFI COMMITS AN ADDITIONAL $625 MILLION TO SANOFI VENTURES TO ACCELERATE INVESTMENT IN BIOTECH AND DIGITAL HEALTH INNOVATION THE FUND WILL REMAIN FOCUSED ON SANOFI'S KEY AREAS OF IMMUNOLOGY, RARE DISEASES, NEUROLOGY, AND VACCINES, BACKING EARLIER-STAGE INNOVATION AND EMERGING OPPORTUNITIES THAT SUPPORT THE COMPANY'S LONG-TERM STRATEGY SANOFI VENTURES DRIVES INNOVATION THROUGH LEADING AND PARTICIPATING IN PRIVATE FINANCING ROUNDS FOR PIONEERING HEALTHCARE COMPANIES PARIS, SEPTEMBER 24, 2025. SANOFI VENTURES HAS ANNOUNCED AN ADDITIONAL $625 MILLION MULTI-YEAR CAPITAL COMMITMENT FROM SANOFI, INCREASING ITS TOTAL ASSETS UNDER MANAGEMENT TO OVER $1.4 BILLION.

PRESS RELEASE: SANOFI COMMITS AN ADDITIONAL $625 MILLION TO SANOFI VENTURES TO ACCELERATE INVESTMENT IN BIOTECH AND DIGITAL HEALTH INNOVATION

AVAILABILITY OF THE Q3 2025 AIDE MMOIRE PARIS, FRANCE  SEPTEMBER 24, 2025. SANOFI ANNOUNCED TODAY THAT ITS Q3 2025 AIDE MMOIRE IS AVAILABLE ON THE "INVESTORS" PAGE OF THE COMPANY'S WEBSITE: THIRD QUARTER 2025 (SANOFI.COM) AS FOR EACH QUARTER, SANOFI PREPARED THIS DOCUMENT TO ASSIST IN THE FINANCIAL MODELLING OF THE GROUP'S QUARTERLY RESULTS.

PRESS RELEASE: AVAILABILITY OF THE Q3 2025 AIDE MMOIRE

SANOFI'S SAR446268 EARNS US FAST TRACK DESIGNATION FOR THE TREATMENT OF NON-CONGENITAL MYOTONIC DYSTROPHY TYPE 1 DESIGNATION EARNED FOR ONE-TIME AAV GENE THERAPY SAR446268, DESIGNED TO SILENCE DMPK EXPRESSION MYOTONIC DYSTROPHY TYPE 1 (DM1) IS A RARE, GENETIC DISORDER THAT CAUSES PROGRESSIVE MUSCLE WEAKNESS AND WASTING, WITH NO CURRENTLY APPROVED MEDICINES PARIS, SEPTEMBER 23, 2025. THE US FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED FAST TRACK DESIGNATION TO SAR446268, SANOFI'S ONE-TIME AAV GENE THERAPY FOR THE TREATMENT OF NON-CONGENITAL (JUVENILE AND ADULT ONSET) DM1 MYOTONIC DYSTROPHY TYPE 1 (DM1).

PRESS RELEASE: SANOFI'S SAR446268 EARNS US FAST TRACK DESIGNATION FOR THE TREATMENT OF NON-CONGENITAL MYOTONIC DYSTROPHY TYPE 1

UPDATE ON THE US REGULATORY REVIEW OF TOLEBRUTINIB IN NON-RELAPSING, SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS PARIS, SEPTEMBER 22, 2025. THE US FOOD AND DRUG ADMINISTRATION (FDA) HAS EXTENDED BY THREE MONTHS THE TARGET ACTION DATE OF ITS REVIEW OF THE NEW DRUG APPLICATION (NDA) OF TOLEBRUTINIB, AN ORAL AND BRAIN-PENETRANT INVESTIGATIONAL BRUTON'S TYROSINE KINASE (BTK) INHIBITOR TO TREAT NON-RELAPSING, SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (NRSPMS) AND TO SLOW DISABILITY ACCUMULATION INDEPENDENT OF RELAPSE ACTIVITY IN ADULT PATIENTS.

PRESS RELEASE: UPDATE ON THE US REGULATORY REVIEW OF TOLEBRUTINIB IN NON-RELAPSING, SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS

SANOFI AND REGENERON'S DUPIXENT TO TREAT CHRONIC SPONTANEOUS URTICARIA ADVANCES IN EU WITH POSITIVE CHMP OPINION RECOMMENDATION FOR ADULTS AND ADOLESCENTS BASED ON PHASE 3 STUDIES SHOWING DUPIXENT SIGNIFICANTLY REDUCED ITCH AND HIVES AT 24 WEEKS COMPARED TO PLACEBO IF APPROVED, DUPIXENT WOULD BE THE FIRST TARGETED MEDICINE IN OVER A DECADE INDICATED FOR CSU IN THE EU PARIS AND TARRYTOWN, SEPTEMBER 22, 2025. THE EUROPEAN MEDICINES AGENCY'S COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) HAS ADOPTED A POSITIVE OPINION RECOMMENDING THE APPROVAL OF DUPIXENT (DUPILUMAB) IN THE EU FOR THE TREATMENT OF CHRONIC SPONTANEOUS URTICARIA (CSU) IN ADULTS AND ADOLESCENTS.

PRESS RELEASE: SANOFI AND REGENERON'S DUPIXENT TO TREAT CHRONIC SPONTANEOUS URTICARIA ADVANCES IN EU WITH POSITIVE CHMP OPINION

EADV: SANOFI'S BRIVEKIMIG ACHIEVED POSITIVE RESULTS IN HIDRADENITIS SUPPURATIVA IN PHASE 2A STUDY IN PHASE 2A STUDY, BRIVEKIMIG LED TO CLINICALLY MEANINGFUL IMPROVEMENTS IN PRIMARY AND KEY SECONDARY ENDPOINTS IN BIOLOGIC-NAVE PATIENTS COMPARED TO PLACEBO AT WEEK 16 DUAL-TARGET NANOBODY VHH INHIBITING TNF AND OX40L BEING EXPLORED ACROSS A RANGE OF IMMUNE-MEDIATED DISEASES REAFFIRMS SANOFI'S COMMITMENT TO ADDRESSING UNDERLYING INFLAMMATION ACROSS COMPLEX, HETEROGENEOUS CHRONIC SKIN DISEASES PARIS, SEPTEMBER 17, 2025. NEW DATA FROM THE HS-OBTAIN PHASE 2A STUDY (CLINICAL STUDY IDENTIFIER: NCT05849922) SHOW THAT TREATMENT WITH BRIVEKIMIG LED TO CLINICALLY MEANINGFUL IMPROVEMENTS IN THE PRIMARY ENDPOINT OF HIDRADENITIS SUPPURATIVA CLINICAL RESPONSE (HISCR50) IN PATIENTS NAVE TO BIOLOGICS WITH MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA (HS).

PRESS RELEASE: EADV: SANOFI'S BRIVEKIMIG ACHIEVED POSITIVE RESULTS IN HIDRADENITIS SUPPURATIVA IN PHASE 2A STUDY

SANOFI'S SAR402663 EARNS FAST TRACK DESIGNATION IN THE US FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION DESIGNATION EARNED FOR A ONE-TIME INTRAVITREAL GENE THERAPY WITH THE POTENTIAL TO ELIMINATE TREATMENT BURDEN FOR PEOPLE LIVING WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION NEOVASCULAR OR WET AGE-RELATED MACULAR DEGENERATION CAN LEAD TO SIGNIFICANT VISION LOSS AND AFFECTS MORE THAN ONE MILLION PEOPLE IN THE US PARIS, SEPTEMBER 11, 2025. THE US FOOD AND DRUG ADMINISTRATION (FDA) HAS GRANTED FAST TRACK DESIGNATION TO SAR402663, AN INVESTIGATIONAL ONE-TIME INTRAVITREAL GENE THERAPY FOR THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD).

PRESS RELEASE: SANOFI'S SAR402663 EARNS FAST TRACK DESIGNATION IN THE US FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

MANDY MOORE JOINS ELAINE WELTEROTH, GABY DALKIN, KATYA ECHAZARRETA, AND SHAWN JOHNSON EAST TO SHARE THEIR PERSONAL RESPIRATORY SYNCYTIAL VIRUS(RSV) STORIES AND WHY THEY CHOSE BEYFORTUS TO HELP PROTECT THEIR BABIES FROM SERIOUS RSV LUNG INFECTION THEY JOIN THE MILLIONS OF PARENTS IN THE US WHO HAVE CHOSEN BEYFORTUS TO HELP PROTECT THEIR BABIES FROM RSV, THE NUMBER ONE REASON BABIES UNDER 1 ARE HOSPITALIZED MORRISTOWN, N.J. , SEPT. 10, 2025 /PRNEWSWIRE/ -- SANOFI IS PARTNERING WITH CELEBRITY MOMS WHO CHOSE TO IMMUNIZE THEIR BABIES WITH BEYFORTUS(NIRSEVIMAB-ALIP) TO HELP EDUCATE FAMILIES ABOUT THE IMPORTANCE OF RSV INFANT PROTECTION.

MANDY MOORE AND CELEBRITY MOM SQUAD JOIN SANOFI TO HELP PROTECT BABIES FROM RSV WITH BEYFORTUS

TZIELD APPROVED IN CHINA AS FIRST DISEASE-MODIFYING THERAPY FOR ADULT AND PEDIATRIC PATIENTS WITH STAGE 2 TYPE 1 DIABETES

Sanofi

SNY

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Sanofi

SNY.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SNY